This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Zanamivir
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
* Date of FDA Approval (Patent Expiration): 1999 (2016) | * Date of FDA Approval (Patent Expiration): 1999 (2016) | ||
* 2009 Sales:$1.1 Billion | * 2009 Sales:$1.1 Billion | ||
| - | * Importance: It was the first [[neuraminidase]] inhibitor to be approved by the FDA, followed a few months later by [[Oseltamivir]]. Newer strains of flu virus, primarily [[H1N1]], have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics. | + | * Importance: It was the first [[neuraminidase]] inhibitor to be approved by the FDA, followed a few months later by [[Oseltamivir]]. Newer strains of flu virus, primarily [[User:Michael Strong/H1N1|H1N1]], have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics. |
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
Revision as of 11:28, 12 December 2010
|
Better Known as: Relenza
- Marketed By: GlaxoSmithKline
- Major Indication: Influenza Infection
- Drug Class: Neuraminidase Inhibitor
- Date of FDA Approval (Patent Expiration): 1999 (2016)
- 2009 Sales:$1.1 Billion
- Importance: It was the first neuraminidase inhibitor to be approved by the FDA, followed a few months later by Oseltamivir. Newer strains of flu virus, primarily H1N1, have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics.
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For References to Pharmacokinetic data, see: References |
||||||||||||||||||||||||||||||||||||||||||
References
